Skip to content

Clinical trials

Observational Muscular Dystrophy, Duchenne trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Muscular Dystrophy, Duchenne Phase: Observational Country / region: United States Clear all

55 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20041
20051
20061
20071
20091
20105
20112
20126
20133
20141
20152
20161
20171
20183
20194
20202
20211
20226
20231
20247
20253
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed24
Recruiting15
Active, not recruiting5
Enrolling by invitation4
Terminated3
Unknown status3
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Cooperative International Neuromuscular Research Group7
University of Florida3
Vanderbilt University Medical Center3
Boston Children's Hospital2
Columbia University2
Massachusetts General Hospital2
National Human Genome Research Institute (NHGRI)2
REGENXBIO Inc.2
Red Nucleus Enterprise Solutions, LLC2
Sarepta Therapeutics, Inc.2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Muscular Dystrophy, Duchenne55
Muscular Dystrophies13
Neuromuscular Diseases5
Muscular Atrophy, Spinal4
Muscular Dystrophies, Limb-Girdle4
Anemia, Sickle Cell3
Cardiomyopathies3
Cystic Fibrosis3
Myotonic Dystrophy3
Rare Diseases3

Trials

Showing 1 to 25 of 55. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.